Background: Blood transfusion is a pathway for the transmission of blood-borne
| INTRODUC TI ON
Blood transfusion is a therapeutic act that saves millions of lives every year worldwide. However, it is also a major source of transmission of pathogens such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV). In 2015, the World Health Organization (WHO) estimated that 37 million people were living with HIV/AIDS worldwide, of whom 25.6 million resided in Africa, the most affected continent by this pandemic.
1 Hepatitis B virus is responsible for about 600 000 deaths worldwide. 2 An estimated 2 billion people are infected with HBV and 248 million are chronic carriers; 3 15%-40% of whom develop hepatic complications such as cirrhosis and hepatocellular carcinoma. Among the four infections diagnosed routinely in Gabon (HIV, HBV, HCV, and syphilis), 6 HIV and HBV are the two major infections observed among blood donors, with seroprevalences of 3.11% for HIV and 7.28% for HBV. 7, 8 In the capital city, Libreville, blood transfusion is validated by the National Blood Transfusion Center (NBTC), which has automated or semi-automated 4th-generation immunoenzymatic assays (COBAS 6000 e601) EVOLIS BioRad (BioRad, Marnes-La-Coquette, France) that ensure ac- 
| Statistical analysis
The performances of RDTs in the detection of HIV and HBsAg were determined using EPI Info version 6.04dfr (CDC, Atlanta, GA, USA).
Sensitivity, specificity, and their 95% confidence intervals are presented.
The Cohen's kappa statistical test (http://graphpad.com/quickcalcs/ kappa/) was used to compare the concordance of RDTs in the detection of serological markers. Results were considered significant for P < 0.05. 
| RE SULTS

| Sensitivity and specificity of RDTs in the detection of HIV
| Sensitivity of BIOSYNEX IMMUNOQUICK ®
HBsAg compared to 4th-generation ELISA (COBAS/ EVOLIS BioRad) in the detection of HBV
| D ISCUSS I ON
Despite the measures taken to improve transfusion safety, a residual risk of transmission of blood-borne pathogens persists. This risk is higher in developing countries. 10 Due to the high prevalence of HIV and HBV in Gabon, the risk of transmission of these pathogens by blood transfusion is even higher compared to other countries where transfusion technology is developed. We assessed the sensitiv- Africa, which ranged from 68.7% to 93.1%.
11
The RDT sensitivities found in this study are lower than those reported in Cameroon where the sensitivity of 12 rapid tests for HIV detection ranged between 93.7% and 100%. 12 The sensitivity of 90.9% for Alere DETERMINE obtained here is lower than that of 98.5% and 98.95% reported in previous studies in Nigeria and South Africa. 13, 14 The difference in RDT sensitivity could be explained by the choice of study populations. RDT sensitivities were evaluated on first-time blood donors who may have donated during seroconversion phase. A previous study in Gabon has shown low sensitivities of RDTs in HIV detection during seroconversion. 15 These low sensitivities of RDTs could also be attributed to the influence of HIV variants, as reported in previous studies. 12, 16 According to the WHO, a highperformance RDT must have a sensitivity >99% for the detection of
HIV.
1 A RDT with lower sensitivity than WHO standards increases the risk of obtaining false negatives, which represents a major challenge in blood transfusion. 17, 18 Alere DETERMINE and BIOSYNEX Exacto® Pro HIV or MEDIFF HIV 1&2 Serum/sang Total Cassette showed a very good concordance of 95.74% for the detection of HIV with a kappa coefficient of 0.912.
In this study, we evaluated the BIOSYNEX IMMUNOQUICK ® HBsAg RDT for the detection of HBV. BIOSYNEX IMMUNOQUICK ® HBsAg sensitivity was 78% (95% CI = 63.7-88.0). This sensitivity is higher than that of 51.5% reported in a previous study that assessed the sensitivity of rapid tests for the detection of HBsAg in blood transfusion centers in Africa. 19 The sensitivity of 78% of BIOSYNEX IMMUNOQUICK ® HBsAg determined in this study is lower than that of 98.5% reported for DETERMINE for the detection of HBsAg.
20
Relatively low antigen levels in blood donors may explain the low sensitivity of the BIOSYNEX IMMUNOQUICK ® HBsAg test in the detection of HBsAg in the latter. 5 All of the rapid diagnostic tests evaluated in this study for both HIV reference in this study for the detection of HIV could present false positives. 21 Also, the Elecsys HIV combi PT kit used by COBAS 6000 e601 was developed to have a higher sensitivity allowing an early detection of HIV in the seroconversion phase. 22 Pending the introduction of the viral genomic diagnosis in blood transfusion in Gabon, EVOLIS BioRad and Cobas 6000 e601 remain the most sensitive tests used in the diagnosis of HIV and HBsAg in blood donors. RDTs evaluated in this study should not be recommended first for blood donation qualification in Gabon, but they could be useful in avoiding blood shortages due to the 4th-generation ELISA reagents breakage in blood centers with limited financial resources. These RDTs could also be used in a predonation test strategy for HIV and HBsAg to reduce the qualifying cost of blood donations. 23, 24 Finally, in remote areas of SSA, in the absence of other diagnostic methods, these RDTs may limit the transmission of HIV and HBV by blood transfusion. 4 Thus, improving blood screening tests is an important factor in reducing the residual risk of transfusion-transmitted infections. 25 
| CON CLUS ION
RDTs offer a new diagnostic opportunity in blood transfusion for lowincome African countries. However, the genomic diversity of HIV and
HBsAg is a serious limit to their uses. Therefore, they must be carefully evaluated and chosen for their use in blood transfusion in Gabon.
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